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qo the Editor: The connection between insulin resistance (IR) and
eart failure (HF) is well recognized (1). Insulin resistance has
epeatedly been demonstrated to be a strong predictor of the devel-
pment of HF and to predict a poor prognosis in patients with HF.
he mechanism by which IR contributes to the pathogenesis of HF
s unclear, but it likely involves the balance between the utilization of
ree fatty acids (FFAs) and glucose as an energy substrate in the
yocardium. Glucose is a more efficient fuel source than FFAs and is
herefore preferentially used under conditions of stress, such as HF. In
tates of IR, this compensatory switch is inhibited, leading to decreased
ardiac efficiency (1).
HF patients without diabetes may demonstrate improvements in
yocardial glucose uptake (MGU) in response to standard therapies
uch as neurohormonal blockade and cardiac resynchronization ther-
py. MGU may also be improved by treatment with metabolic
odulators. Interventions that improve insulin sensitivity (e.g., diet
odification, insulin-sensitizing agents, gene overexpression/
nderexpression) seem to protect against myocardial injury in animal
odels (2). Consequently, there is growing interest in the role of
harmacologic modulation of myocardial FFAs and glucose utiliza-
ion as an adjunct therapy for selected patients with HF (1).
We propose that patients with HF and IR may demonstrate
mprovement in MGU after treatment with insulin-sensitizing
gents. We describe the findings of a pilot study to measure MGU
lterations using serial fluorodeoxyglucose (FDG) positron emission
omography (PET) before and after treatment with rosiglitazone, a
eroxisome proliferator-activated receptor gamma agonist. Our goal
as to demonstrate that alteration of whole-body insulin sensitivity
an result in quantifiable improvements in MGU, even in the absence
f frank diabetes mellitus (DM).
Patients with nonischemic dilated cardiomyopathy and New York
eart Association functional class I to II HF who had been on a
table medication and device regimen for at least 3 months were
ligible for screening. Fasting insulin and glucose levels were used to
alculate the Homeostasis Model Assessment for IR for eligible
atients. Patients underwent a 6-min walk test, fasting lipid studies,
nd an FDG-PET study to assess MGU at baseline and after a
-week course of rosiglitazone, 4 mg/day.
The FDG-PET/computed tomography (CT) scans were per-
ormed using a Discovery LS PET/CT unit (GE Medical Systems,
ilwaukee, Wisconsin). Patients fasted for at least 6 h before
maging, and their blood glucose levels were 150 mg/dl at the time
f the study. Four multislice helical noncontrast CT images were
btained over the thorax to be used for attenuation correction
urposes and anatomic localization. Subjects then received a 50-g oral
lucose load and 20-mCi FDG injection, followed by serial PET
cquisition at 0, 29, 39, 49, and 59 min. The PET scan was corrected
sing segmented attenuation data of the conventional transmission
can. PET images were reconstructed with a standard iterative
lgorithm. All images were reformatted into axial, coronal, and tagittal views and viewed with the software provided by the manu-
acturer (eNTEGRA, GE Medical Systems, Haifa, Israel).
Seven patients enrolled in the protocol and received baseline
tudies. Three subjects withdrew during the treatment phase; 2
ithdrew because of fluid retention and 1 because of lightheadedness.
our subjects completed the full course of treatment, and 3 subjects
ad baseline and follow-up PET scans of sufficient quality for analysis,
hereas the follow-up scan for 1 subject was corrupted and uninter-
retable. All patients were on standard HF medications including
eta-blockers and angiotensin-converting enzyme inhibitors. Ho-
eostasis Model Assessment for IR values of the 3 subjects with
omplete imaging were 6.67, 1.78, and 0.64. Two subjects (data
navailable for subject #1) demonstrated a confirmed decrease in
omeostasis Model Assessment for IR after treatment, correspond-
ng with improved insulin sensitivity. Although all 3 subjects demon-
trated an increase in MGU by FDG-PET, the increase was much
ore dramatic with increasing levels of baseline IR (Fig. 1). There
ere no significant changes in 6-min walk distance or weight in any
f the subjects.
FDG-PET studies in humans with DM have demonstrated
mpaired MGU in the setting of normal myocardial systolic function.
lthough this impairment was ameliorated by treatment with rosigli-
azone, studies using insulin secretagogues and metformin to improve
GU have shown mixed results (4). Peroxisome proliferator-
ctivated receptor gamma receptors are predominantly found in
dipose tissue and are most commonly associated with modulation of
hole-body insulin sensitivity and a decrease in circulating FFAs.
mprovement in MGU in response to rosiglitazone may be related to
uppression of FFA levels, given that there is little peroxisome
roliferator-activated receptor gamma expression in the myocardium.
lthough this has been studied previously in patients with type 2
M, to our knowledge, our study is the first demonstration of
mprovement in MGU with an insulin-sensitizing agent in patients
ith HF in the absence of DM.
Use of thiazolidinediones in HF has been limited by the side effect
f fluid retention, and 2 of 7 of our subjects withdrew because of fluid
etention. Our study size was also limited by our decision to end
nrollment of new subjects in August 2007 when the U.S. Food and
rug Administration decided to add a black-box warning for the use
f rosiglitazone in HF in light of concerns about the safety of
hiazolidinediones in the presence of heart disease (5). Consequently,
ther drugs may be better suited for further study of metabolic
odulation in HF. Trimetazidine is an antianginal agent that
romotes glucose metabolism by inhibiting the final step of FFA
-oxidation, and it has been shown in a placebo-controlled, crossover
tudy (6) to improve left ventricular function and high-energy phos-
hate levels in heart failure. Glucagon-like peptide 1, which stimulates
nsulin secretion and insulin sensitivity, has been shown to improve
uality of life and measures of left ventricular function, suggesting that
he glucagon-like peptide 1 receptor agonists (e.g., exenatide) and the
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March 2, 2010:926–33ipeptidyl-peptidase IV inhibitors (e.g., sitagliptin) may also merit
urther study as adjunct therapies for HF in the setting of IR.
Our results suggest that MGU in patients with nonischemic
ilated cardiomyopathy may be improved through modulation of
hole-body insulin sensitivity, even in the absence of DM, and that
atients with higher degrees of IR may derive more benefit from such
herapy than insulin-sensitive patients.
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Figure 1 Myocardial Glucose Uptake Before and After Treatment With R
Note how the glucose uptake increases in all subjects, but much more dramatical
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